Anthera Pharmaceuticals, Inc. (ANTH)
Stock Price: $0.116 USD
-0.055 (-32.06%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
| Market Cap | 399,773 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.93M |
| Shares Out | 22.17M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $0.116 |
| Previous Close | $0.170 |
| Change ($) | -0.055 |
| Change (%) | -32.06% |
| Day's Open | 0.170 |
| Day's Range | 0.101 - 0.170 |
| Day's Volume | 972,188 |
| 52-Week Range | - |
News
There are no news available yet.
About ANTH
Anthera Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreem... [Read more...]
| Industry Biotechnology | IPO Date Mar 1, 2010 |
| CEO J. Craig Thompson | Employees 21 |
| Stock Exchange OTCMKTS | Ticker Symbol ANTH |